dextromethorphan and Vascular-Calcification

dextromethorphan has been researched along with Vascular-Calcification* in 1 studies

Other Studies

1 other study(ies) available for dextromethorphan and Vascular-Calcification

ArticleYear
Dextromethorphan Reduces Oxidative Stress and Inhibits Uremic Artery Calcification.
    International journal of molecular sciences, 2021, Nov-13, Volume: 22, Issue:22

    Medial vascular calcification has emerged as a key factor contributing to cardiovascular mortality in patients with chronic kidney disease (CKD). Vascular smooth muscle cells (VSMCs) with osteogenic transdifferentiation play a role in vascular calcification. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors reduce reactive oxygen species (ROS) production and calcified-medium-induced calcification of VSMCs. This study investigates the effects of dextromethorphan (DXM), an NADPH oxidase inhibitor, on vascular calcification. We used in vitro and in vivo studies to evaluate the effect of DXM on artery changes in the presence of hyperphosphatemia. The anti-vascular calcification effect of DXM was tested in adenine-fed Wistar rats. High-phosphate medium induced ROS production and calcification of VSMCs. DXM significantly attenuated the increase in ROS production, the decrease in ATP, and mitochondria membrane potential during the calcified-medium-induced VSMC calcification process (

    Topics: Animals; Cell Line; Dextromethorphan; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Rats; Rats, Inbred WKY; Uremia; Vascular Calcification

2021